; 111 : 1805 – 1810 . 16. Spencer A Prince HM Roberts AW . Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure
Search Results
The Role of Maintenance Therapy in the Treatment of Multiple Myeloma
Ashraf Z. Badros
Lung Cancer Survivorship: Physical, Social, Emotional, and Medical Needs of NSCLC Survivors
Melinda L. Hsu, Matthew Z. Guo, Sarah Olson, Cyd Eaton, Mary Boulanger, Michelle Turner, Mattea E. Miller, Anna Nguyen, Karol Szczepanek, Rahul Shenolikar, and Josephine L. Feliciano
pemetrexed following treatment with pembrolizumab, carboplatin, and pemetrexed) and consolidation therapy (ie, durvalumab following treatment with definitive chemoradiation) were not counted as additional lines of therapy. These distinctions were used to
Care Patterns and Barriers to Outpatient Care for Adults With AML Following Intensive Chemotherapy at NCCN Member Institutions
Anna B. Halpern, Jessica M. Sugalski, Lindsey Bandini, Megan Othus, F. Marc Stewart, and Roland B. Walter
patients early less frequently. Table 1. Formal Discharge Criteria for Early Hospital Discharge (N=5) Practice Patterns Following Postremission Chemotherapy We next examined how centers deliver care following postremission (“consolidation
Acute Lymphoblastic Leukemia
Joseph C. Alvarnas, Patrick A. Brown, Patricia Aoun, Karen Kuhn Ballen, Naresh Bellam, William Blum, Michael W. Boyer, Hetty E. Carraway, Peter F. Coccia, Steven E. Coutre, Jennifer Cultrera, Lloyd E. Damon, Daniel J. DeAngelo, Dan Douer, Haydar Frangoul, Olga Frankfurt, Salil Goorha, Michael M. Millenson, Susan O'Brien, Stephen H. Petersdorf, Arati V. Rao, Stephanie Terezakis, Geoffrey Uy, Meir Wetzler, Andrew D. Zelenetz, Maoko Naganuma, and Kristina M. Gregory
-negative ALL can be further categorized as having high-risk disease, which may be particularly helpful when consolidation therapy with allogeneic HSCT is being considered. High risk is defined as having any of the following poor-risk factors: elevated WBC count
Biologic Agents in the Management of Hodgkin Lymphoma
Armin Rashidi and Nancy L. Bartlett
AETHERA study ( ClinicalTrials.gov identifier: NCT01100502), evaluating BV as consolidation therapy after auto-SCT in high-risk patients. 40 Patients had primary refractory disease, or experienced disease relapse either less than 12 months after
Controversies Regarding Use of Myeloid Growth Factors in Leukemia
Jacqueline N. Poston and Pamela S. Becker
; 106 : 27 – 34 . 29. Heil G Hoelzer D Sanz MA . A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia . Blood 1997
Addition of Definitive Radiotherapy to Chemotherapy in Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer
Vivek Verma, Pamela K. Allen, Charles B. Simone II, Hiram A. Gay, and Steven H. Lin
2014 ; 32 : 3824 – 3830 . 11. Gomez DR Blumenschein GR Jr Lee JJ . Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first
Role of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid Leukemia
Hany Elmariah and Keith W. Pratz
Background For 40 years, standard therapy for acute myeloid leukemia (AML) has remained infusional cytarabine/anthracycline–based induction chemotherapy to achieve remission, followed typically by high-dose cytarabine consolidative therapy to
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
Daniel A. Pollyea, Jessica K. Altman, Rita Assi, Dale Bixby, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Brian A. Jonas, Ashwin Kishtagari, Jeffrey Lancet, Lori Maness, James Mangan, Gabriel Mannis, Guido Marcucci, Alice Mims, Kelsey Moriarty, Moaath Mustafa Ali, Jadee Neff, Reza Nejati, Rebecca Olin, Mary-Elizabeth Percival, Alexander Perl, Amanda Przespolewski, Dinesh Rao, Farhad Ravandi, Rory Shallis, Paul J. Shami, Eytan Stein, Richard M. Stone, Kendra Sweet, Swapna Thota, Geoffrey Uy, Pankit Vachhani, Carly J. Cassara, Deborah A. Freedman-Cass, and Katie Stehman
options include low-intensity therapy with venetoclax-based regimens, steroids, and supportive care. Postremission Surveillance for BPDCN Following completion of consolidation therapy, it is recommended to monitor a CBC, including platelets
Hematopoietic Progenitor Cell Transplantation in Children, Adolescents, and Young Adults With Relapsed Mature B-Cell NHL
Aliza Gardenswartz and Mitchell S. Cairo
‐cell non Hodgkin lymphoma [abstract] . Br J Haematol 2018 ; 182 ( Suppl 1 ): Abstract 28 . 25. Moskowitz CH , Nademanee A , Masszi T , . Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with
